Skip to main content
Richard Ambinder, MD, Oncology, Baltimore, MD, Johns Hopkins Hospital

RichardFAmbinderMD

Oncology Baltimore, MD

Professor of Oncology, Professor of Medicine, Professor of Pathology, Johns Hopkins University School of Medicine; Director, Division of Hematologic Malignancies, Program Leader, Hematologic Malignancies and Bone Marrow Transplant, James B. Murphy Professor

Dr. Ambinder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ambinder's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1979 - 1982
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1979
  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Medical Oncology

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2023 - 2026
  • MD State Medical License
    MD State Medical License 1979 - 2024
  • PA State Medical License
    PA State Medical License 2020 - 2022
  • MI State Medical License
    MI State Medical License 1980 - 1982
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
    Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
    Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
    Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Rel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • 5th Annual T-cell Lymphoma Forum 
    Jonathan Wood & Associates, San Francisco, California - 1/24/2013

Other

Press Mentions

  • Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin Lymphoma
    Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin LymphomaDecember 3rd, 2018
  • HIV-Associated Cancers: A Paradigm Shift?
    HIV-Associated Cancers: A Paradigm Shift?April 19th, 2018
  • Liquid Biopsies Study Boosts Cancer Detection Hope
    Liquid Biopsies Study Boosts Cancer Detection HopeAugust 17th, 2017
  • Join now to see all

Hospital Affiliations